Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 1/2009

01-02-2009 | CE - Letter to the Editor

Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies: only in selected, high risk patients

Authors: Mario Bazzan, Antonella Vaccarino

Published in: Internal and Emergency Medicine | Issue 1/2009

Login to get access

Excerpt

The antiphospholipid syndrome (APS) was first described in 1983 [1], and the recent Consensus Conference held in Sydney in 2006 quite clearly defines laboratory (antiphospholipid [aPL] antibodies—assays and cut off values) and clinical criteria for the diagnosis of APS syndrome [2]. Defining these criteria is more closely related to research purposes than to clinical practice, thus avoiding enrollment of patients with aspecific types of positivity into clinical trials or laboratory studies. …
Literature
1.
Harris EN, Gharavi AE, Boey ML et al (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2:1211–1214PubMedCrossRef
2.
Myakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on update of classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4:295–306CrossRef
3.
Gerosa M, Chighizola C, Meroni PL (2008) Aspirin in asymptomatic patients with confirmed positivity of anti phospholipids antibodies? Yes (in some cases). Intern Emerg Med 3:201–203PubMedCrossRef
4.
Finazzi G (2008) Aspirin in asymptomatic patients with confirmed positivity of anti phospholipids antibodies? No. Intern Emerg Med 3:197–200PubMedCrossRef
5.
Giron-Gonzales JA, Garcia del Rio E, Rodriguez C et al (2004) Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 31:1560–1567
6.
Forastiero R, Martinuzzo M, Pombo G et al (2005) A prospective study of antibodies to β2-glycoprotein I and prothrombin and risk of thrombosis. J Thromb Haemost 3:1231–1238PubMedCrossRef
7.
Shah NM, Khamashta MA, Atsumi T et al (1998) Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 7:3–6PubMedCrossRef
8.
Erkan D, Harrison MJ, Levy R et al (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome. Arthritis Rheum 56:2382–2391PubMedCrossRef
9.
Erkan D, Merril JT, Yazici Y et al (2001) High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 44:1466–1469PubMedCrossRef
Metadata
Title
Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies: only in selected, high risk patients
Authors
Mario Bazzan
Antonella Vaccarino
Publication date
01-02-2009
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 1/2009
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-008-0209-0

Other articles of this Issue 1/2009

Internal and Emergency Medicine 1/2009 Go to the issue

IM - Review

Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease?

CE - Letter to the Editor

Older adults use the emergency department appropriately

CE - The Cutting Edge: Research Update

New evidence in oncologic and cardiocirculatory medicine

CE - Cochrane's Corner

Commercial dressings for burns versus sweet ancient remedy

CE - Letter to the Editor

Can nonalcoholic steatohepatitis trigger porphyria cutanea tarda clinical manifestations?

CE - Letter to the Editor

Budd-Chiari syndrome in a paroxysmal nocturnal hemoglobinuria patient with previous cerebral venous thrombosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits